Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis
Ji-Yun Lee(University of Seoul), Kihyun Kım(State University of New York), Jin‐Oh Choi, Sung Hee Lim(Samsung Medical Center), Jung Eun Lee(Sookmyung Women's University), Hee‐Jin Kim(Samsung Medical Center), Jung-Sun Kim(Oregon Health & Science University), Soo‐Youn Lee(Sungkyunkwan University), Ga Yeon Lee(Samsung Medical Center), Seok Jin Kim(Samsung (South Korea)), Ju‐Hong Min(Samsung (South Korea)), Eun‐Seok Jeon
Cited by 23
Related Papers
Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA–PEG block copolymers
|Journal of Controlled Release|2003|793
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts
|JNCI Journal of the National Cancer Institute|2018|285
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
|Multiple Sclerosis Journal|2011|284
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2024|162